证券代码：300677 证券简称：英科医疗 公告编号：2025-063 英科医疗科技股份有限公司 关于召开公司 2025 年第三次临时股东大会的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）已于 2025 年 司 2025 年第三次临时股东大会的通知》（公告编号：2025-060），为 保护投资者权益，方便公司股东行使股东大会表决权，现将有关事项 再次提示如下： 一、召开会议的基本情况 律、法规、部门规章、规范性文件及《英科医疗科技股份有限公司章 程》的规定。 （1）现场会议召开时间：2025 年 5 月 16 日（星期五）14:00 （2）网络投票时间：2025 年 5 月 16 日。其中，通过深圳证券交 易所交易系统进行网络投票的时间为 2025 年 5 月 16 日 9:15-9:25， 体时间为 2025 年 5 月 16 日 9:15-15:00。 司将通过深圳证券交易所交易系统和互联网投票系统 （http://wltp.cninfo.com.cn）向公司股东提供网络形式的投票平台，股 东可以在网络 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Yingke Medical, which has a current PE ratio of 9.49, significantly lower than the industry average of 49.84 [1][2] - As of March 31, 2025, Yingke Medical has 61,786 shareholders, an increase of 1,641 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - Yingke Medical operates as a comprehensive supplier of medical care products, with main business segments including medical protection, rehabilitation care, health therapy, and examination consumables [1] Group 2 - The latest financial results for Yingke Medical show a revenue of 2.494 billion yuan for Q1 2025, representing a year-on-year increase of 13.20%, and a net profit of 353 million yuan, up 48.08% year-on-year, with a gross margin of 24.16% [1] - In terms of market capitalization, Yingke Medical is valued at 14.992 billion yuan, ranking 31st in the medical device industry [1][2] - The industry median PE ratio is 36.59, indicating that Yingke Medical is trading at a significant discount compared to its peers [2]

证券代码：300677 证券简称：英科医疗 公告编号：2025-064 英科医疗科技股份有限公司 关于参加 2025 年山东辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，英科医疗科技股份有限公司 （以下简称"公司"）将参加由山东证监局、山东上市公司协会与深 圳市全景网络有限公司联合举办的"2025 年山东辖区上市公司投资 者网上集体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站（http://rs.p5w.net）；或关注微信公众号（名称：全景财经）； 或下载全景路演 APP，参与本次互动交流。活动时间为 2025 年 5 月 15 日（周四）15:00-16:30。届时公司高管将在线就公司 2024 年度业 绩、公司治理、发展战略、经营状况、融资计划、股权激励和可持续 发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资 者踊跃参与！ 特此公告！ 英科医疗科技股份有限公司 董 事 会 2025 年 5 月 13 日 ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-063 1、股东大会届次：2025 年第三次临时股东大会 2、召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召开符合有关法 律、法规、部门规章、规范性文件及《英科医疗科技股份有限公司章 程》的规定。 4、会议召开的日期、时间 （1）现场会议召开时间：2025 年 5 月 16 日（星期五）14:00 （2）网络投票时间：2025 年 5 月 16 日。其中，通过深圳证券交 易所交易系统进行网络投票的时间为 2025 年 5 月 16 日 9:15-9:25， 英科医疗科技股份有限公司 关于召开公司 2025 年第三次临时股东大会的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 29 日在巨潮资讯网（www.cninfo.com.cn）发布了《关于召开公 司 2025 年第三次临时股东大会的通知》（公告编号：2025-060），为 保护投资者权益，方便公司股东行使股东大会表决权，现将有关事项 再次提示如下： ...

Market Performance - The Shanghai Composite Index and Shenzhen Component Index experienced declines of 0.30% and 0.69% respectively on May 5, 2025, while the ChiNext Index and STAR Market 50 fell by 0.87% and 1.96% respectively [1] - Among 33 A-share companies in Zibo, 30 saw an increase, 1 remained flat, and 2 declined during the same period [1] Notable Stock Movements - Weiming Pharmaceutical (002581) achieved a remarkable 23.29% increase over five days, leading the gains [1] - Yahua Electronics (301337) and Jincheng Pharmaceutical (300233) also saw significant increases of 17.30% and 11.31% respectively [1] - On May 7, PEEK material concept stocks surged, with Zhongxin Fluorine Materials (002915) hitting the daily limit for the sixth time in nine days, and Kaisheng New Materials (301069) rising by 2.29% with a trading volume of 4.02 billion yuan [1] Company Announcements - Kehui Co., Ltd. announced a share repurchase plan with a budget between 9 million and 16 million yuan, with a maximum repurchase price of 17 yuan per share, aimed at employee stock ownership plans [1] Financial Results - Furuida (600223) reported a revenue of 526 million yuan in its cosmetics segment for Q1 2025, with a gross margin of 61.06% [3] - Qichang Tenda (002408) achieved total revenue of 5.618 billion yuan in Q1 2025, a year-on-year increase of 2.53%, but saw a significant drop in net profit by 83.18% to 5.4007 million yuan [3] - Xinhua Medical (600587) reported a total revenue of 2.308 billion yuan, down 8.74% year-on-year, with a net profit decline of 23.97% to 160 million yuan [3] - Bohui Paper (600966) reported a total revenue of 4.564 billion yuan, a 3.77% increase year-on-year, but a net profit decline of 46.91% to 53.3737 million yuan [3] Market Capitalization - In terms of market capitalization, Yingke Medical (300677) led with 14.708 billion yuan, followed closely by Shandong Pharmaceutical Glass (600529) at 14.626 billion yuan, and Qichang Tenda (002408) at 12.963 billion yuan [4]

Core Insights - The total revenue of 33 A-share listed companies in Zibo for 2024 is approximately 147.77 billion yuan, with 23 companies showing revenue growth compared to the previous year [1][2] - The total net profit for these companies is around 6.66 billion yuan, with 19 companies experiencing a year-on-year increase in net profit [1][8] Revenue Performance - 23 companies achieved positive revenue growth, while 10 companies reported declines [2] - Three companies surpassed the 10 billion yuan revenue mark: Qixiang Tengda (25.22 billion yuan), Bohui Paper (18.93 billion yuan), and Xinhua Medical (10.02 billion yuan) [2][4] - Qixiang Tengda remains the revenue leader despite a 6.31% decline in revenue [4] - Bohui Paper produced 4.53 million tons of paper, achieving a revenue of 18.93 billion yuan, a 1.27% increase [4] - Xinhua Medical's revenue increased slightly by 0.09%, with significant growth in its pharmaceutical equipment segment [4][5] Profitability Analysis - The total net profit of 33 companies is approximately 6.66 billion yuan, with notable profit leaders being Yingke Medical (1.47 billion yuan), Shandong Yaobang (943 million yuan), and Xinhua Medical (692 million yuan) [8][9] - Yingke Medical's net profit surged by 282.63%, marking it as the most profitable company [9][10] - 19 companies reported an increase in net profit, while 14 companies experienced declines [8][12] - Five companies saw net profit declines exceeding 50%, with Yahua Electronics reporting a significant loss of 26 million yuan [12][13] Notable Companies - Yingke Medical's production capacity utilization reached 100%, with a recovery in sales prices compared to 2023 [10] - Bohui Paper's strong production capacity contributed to its stable revenue growth [4] - Xinhua Medical is expanding its international presence with five overseas sales centers [5] - Blue Sail Medical, despite a revenue increase of 26.91%, reported a loss of 446 million yuan [16]

Core Viewpoint - In 2025, Yingke Medical Technology Co., Ltd. continues to show growth, with Q1 revenue reaching 2.494 billion yuan, a year-on-year increase of 13.2%, and net profit attributable to shareholders at 353 million yuan, up 48.08% [1] Group 1: Financial Performance - The company reported Q1 2025 revenue of 2.494 billion yuan, reflecting a 13.2% year-on-year growth [1] - Net profit for the same period was 353 million yuan, marking a significant increase of 48.08% [1] Group 2: Production Capacity and Market Trends - Yingke Medical's annual production capacity for disposable non-latex gloves has reached 87 billion units, with nitrile gloves accounting for 56 billion units and PVC gloves for 31 billion units, maintaining a product quality rate of over 99% [1] - The global market for disposable gloves is projected to reach 82.93 billion units in sales volume and 13.6 billion USD in revenue by 2025, with nitrile gloves gaining prominence in various sectors due to their safety and functionality [1] Group 3: Product Diversification and Market Strategy - The company is increasing investments in rehabilitation and other product areas, including wheelchairs and various medical supplies, driven by the growing demand from an aging population [2] - Yingke Medical is implementing a dual strategy of efficient supply chain management and penetration into emerging markets, establishing marketing service centers in Malaysia and Vietnam [2] - The company is enhancing its overseas supply chain and production capabilities to build a regional supply system that covers major markets, thereby improving risk resilience [2]

Core Viewpoint - Inke Medical's stock closed at 22.55 yuan, with a PE ratio of 9.22, significantly lower than the industry average of 48.90 [1][2] Company Overview - Inke Medical Technology Co., Ltd. is a comprehensive supplier of medical care products, focusing on four main business segments: medical protection, rehabilitation care, health therapy, and examination consumables [1] - The company's main products include disposable gloves, wheelchairs, hot and cold packs, and electrode pads, establishing it as a leading global supplier of medical consumables [1] Financial Performance - For Q1 2025, Inke Medical reported revenue of 2.494 billion yuan, a year-on-year increase of 13.20%, and a net profit of 353 million yuan, up 48.08% year-on-year, with a gross profit margin of 24.16% [1] Market Position - Inke Medical ranks 31st in the medical device industry based on PE ratio, with an overall market capitalization of 14.572 billion yuan [1][2] - The industry median PE ratio is 36.41, indicating that Inke Medical's valuation is significantly below the industry average [2] Capital Flow - On May 6, 2023, Inke Medical experienced a net outflow of 19.14 million yuan in principal funds, continuing a trend of outflows over the past five days, totaling 8.31 million yuan [1]

英科医疗科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2024 年 9 月 19 日召开第三届董事会第二十五次会议和第三届监事会第二十三 次会议，审议通过了《关于公司回购股份方案的议案》，同意公司使 用不低于人民币 8,000 万元（含本数）且不超过人民币 12,000 万元 （含本数）的自有资金，以集中竞价交易的方式回购部分公司股份（人 民币普通股（A 股）股票），用于实施员工持股计划及/或股权激励。 回购价格不超过人民币 26.61 元/股（含本数），回购股份的数量和金 额以回购期限届满时实际回购的股份数量和金额为准。回购股份的实 施期限为自公司第三届董事会第二十五次会议审议通过本次回购股 份方案之日起不超过 12 个月。具体内容详见公司分别于 2024 年 9 月 19 日、2024 年 9 月 20 日和 2024 年 10 月 31 日披露于巨潮资讯网 （www.cninfo.com.cn）上的《关于公司回购股份方案的公告》（公告 编号：2024-093）、《回 ...

本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：300677 证券简称：英科医疗 公告编号：2025-054 英科医疗科技股份有限公司 第四届董事会第三次会议决议公告 二、董事会会议审议情况 1、审议通过《关于<2025年第一季度报告>的议案》 董事会认为《2025年第一季度报告》的内容真实、准确和完整， 没有虚假记载、误导性陈述或者重大遗漏。 本议案已经公司第四届董事会审计委员会第三次会议审议通过。 1 一、董事会会议召开情况 英科医疗科技股份有限公司（以下简称"公司"）第四届董事会 第三次会议于 2025 年 4 月 28 日在公司会议室以现场结合通讯方式召 开，会议通知已于 2025 年 4 月 26 日以专人送达、电子邮件、传真或 即时通讯工具等形式向全体董事发出。会议由公司董事长刘方毅先生 召集和主持，本次会议应出席董事 7 名，实际出席会议董事 7 名，公 司部分监事和高级管理人员列席了本次会议。会议的召集和召开符合 《中华人民共和国公司法》《英科医疗科技股份有限公司章程》（以下 简称"《公司章程》"）的有关规定。 具体内容详见同日刊登于巨潮资 ...